Skip to main content
. Author manuscript; available in PMC: 2021 Apr 14.
Published in final edited form as: Mol Cancer Res. 2020 Apr 22;18(8):1189–1201. doi: 10.1158/1541-7786.MCR-19-1144

Figure 3.

Figure 3.

Debio-025 treatment inhibits cell migration in a CypA-dependent manner. A, Tumor cell migration in response to Debio-025 treatment. DU145, MDA-MB-231, and Hs683 cells were assessed for tumor cell migration using XCELLigence assay toward serum gradient. B, Western blotting analysis of CypA knockdown using shRNA in MDA-MB-231 cells. C, Determination of effect of scramble (Scr) and CypA knockdown on migration of MDA-MB-231 cells. D, Cell proliferation assays using CellTiter-Glo luminescent cell viability assay on DU145, MDA-MB-231, and Hs683 cells to test the effect of the Debio-025 on cell proliferation of cancer cells. Error bars, SD; all P values are based on one-sided Student t tests. **, P < 0.001; ***, P < 0.001; ns, nonsignificant; WT, wild-type.